Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the potential of early treatment with CAR-T therapy or bispecific antibodies for patients with smoldering multiple myeloma (SMM), highlighting remaining questions in this space. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.